Josefin-Beate Holz

833 total citations
34 papers, 612 citations indexed

About

Josefin-Beate Holz is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Surgery. According to data from OpenAlex, Josefin-Beate Holz has authored 34 papers receiving a total of 612 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Surgery. Recurrent topics in Josefin-Beate Holz's work include Platelet Disorders and Treatments (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Antiplatelet Therapy and Cardiovascular Diseases (5 papers). Josefin-Beate Holz is often cited by papers focused on Platelet Disorders and Treatments (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Antiplatelet Therapy and Cardiovascular Diseases (5 papers). Josefin-Beate Holz collaborates with scholars based in Belgium, United States and Germany. Josefin-Beate Holz's co-authors include Hans Ulrichts, Jan Roodt, Sofie Priem, Stefaan Rossenu, Jozef Bartúnek, Emanuele Barbato, William Wijns, Guy R. Heyndrickx, Marc Vanderheyden and Katrien Verschueren and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Josefin-Beate Holz

33 papers receiving 598 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Josefin-Beate Holz Belgium	11	241	183	181	161	114	34	612
Jian-Ming Gu United States	14	104 0.4×	767 4.2×	143 0.8×	37 0.2×	120 1.1×	21	978
Maciej Kaźmierczak Poland	13	63 0.3×	194 1.1×	161 0.9×	61 0.4×	30 0.3×	41	475
Vicente Baca Mexico	14	321 1.3×	97 0.5×	169 0.9×	53 0.3×	18 0.2×	21	681
Miao Qi Australia	11	109 0.5×	116 0.6×	106 0.6×	77 0.5×	65 0.6×	27	452
SA Burstein United States	11	97 0.4×	398 2.2×	125 0.7×	25 0.2×	43 0.4×	20	575
Anhquyen Le United States	9	131 0.5×	130 0.7×	276 1.5×	26 0.2×	55 0.5×	16	444
F. Scheiflinger Austria	14	224 0.9×	405 2.2×	67 0.4×	26 0.2×	37 0.3×	25	594
Nele Vandeputte Belgium	15	445 1.8×	427 2.3×	74 0.4×	31 0.2×	51 0.4×	23	710
Cindy Varga United States	17	47 0.2×	371 2.0×	519 2.9×	35 0.2×	34 0.3×	60	746
Annachiara Mitrugno United States	14	145 0.6×	191 1.0×	184 1.0×	20 0.1×	76 0.7×	18	688

Countries citing papers authored by Josefin-Beate Holz

Since Specialization

Citations

This map shows the geographic impact of Josefin-Beate Holz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Josefin-Beate Holz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Josefin-Beate Holz more than expected).

Fields of papers citing papers by Josefin-Beate Holz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Josefin-Beate Holz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Josefin-Beate Holz. The network helps show where Josefin-Beate Holz may publish in the future.

Co-authorship network of co-authors of Josefin-Beate Holz

This figure shows the co-authorship network connecting the top 25 collaborators of Josefin-Beate Holz. A scholar is included among the top collaborators of Josefin-Beate Holz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Josefin-Beate Holz. Josefin-Beate Holz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Scully, Marie, Spero R. Cataland, Paul Coppo, et al.. (2025). Novel von willebrand factor targeting thrombolytic TGD001 is safe and well tolerated in a phase 1 first-in-human trial. Blood. 146(Supplement 1). 849–849.

Schümann, Michael, J. G. A. Houbiers, Yolande Chvatchko, et al.. (2024). 789 CALY-002, AN ANTI-IL-15 ANTIBODY, PREVENTS GLUTEN CHALLENGEINDUCED MUCOSAL DAMAGE AND INFLAMMATION: RESULTS FROM A PHASE 1A/B STUDY. Gastroenterology. 166(5). S–194. 3 indexed citations

Moser, Justin C., et al.. (2024). Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL-3 inhibitor, in patients with advanced malignancies.. Journal of Clinical Oncology. 42(16_suppl). 2586–2586. 10 indexed citations

Bredenoord, Arjan, J. G. A. Houbiers, Tim Vanuytsel, et al.. (2024). 962 CALY-002, AN ANTI-IL-15 ANTIBODY, RESULTS IN HISTOLOGICAL AND CLINICAL IMPROVEMENT IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS IN A PHASE 1A/B STUDY. Gastroenterology. 166(5). S–228. 2 indexed citations

Ofir-Rosenfeld, Yaara, et al.. (2023). Abstract C077: STC-15, a small molecule inhibitor of the RNA methyltransferase METTL3, activates anti-tumor immunity and reshapes the tumor microenvironment. Molecular Cancer Therapeutics. 22(12_Supplement). C077–C077. 1 indexed citations

Holz, Josefin-Beate, et al.. (2022). Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report. Journal for ImmunoTherapy of Cancer. 10(10). e005225–e005225. 6 indexed citations

Yap, Timothy A., Siwen Hu‐Lieskovan, Kyriakos P. Papadopoulos, et al.. (2020). 395 A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy. Regular and Young Investigator Award Abstracts. A240–A240. 11 indexed citations

Rinaldi, Manuela, Tinneke Denayer, Sophie Thiolloy, et al.. (2013). ALX-0962, an anti-IgE Nanobody® with a dual mode of action. European Respiratory Journal. 42(Suppl 57). 1765–1765. 5 indexed citations

Roy, Maarten Van, et al.. (2013). FRI0021 Alx-0061, an anti-IL-6r nanobody® for therapeutic use in rheumatoid arthritis, demonstrates in vitro a differential biological activity profile as compared to tocilizumab. Annals of the Rheumatic Diseases. 72. A375–A375. 4 indexed citations

10.

Callewaert, Filip, Jan Roodt, Hans Ulrichts, et al.. (2012). Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood. 120(17). 3603–3610. 106 indexed citations

11.

Holz, Josefin-Beate. (2012). The TITAN trial – Assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura. Transfusion and Apheresis Science. 46(3). 343–346. 40 indexed citations

12.

Müller, Olivier, Jozef Bartúnek, Michalis Hamilos, et al.. (2012). von Willebrand Factor Inhibition Improves Endothelial Function in Patients with Stable Angina. Journal of Cardiovascular Translational Research. 6(3). 364–370. 24 indexed citations

13.

Bartúnek, Jozef, Emanuele Barbato, Christian Duby, et al.. (2010). Abstract 15084: Safety and Efficacy of Anti-von Willebrand Factor Nanobody® ALX-0081 in Stable Angina Patients Undergoing Percutaneous Coronary Intervention. Circulation. 122. 6 indexed citations

14.

Müller, Olivier, Michalis Hamilos, Jozef Bartúnek, et al.. (2009). Relation of Endothelial Function to Residual Platelet Reactivity After Clopidogrel in Patients With Stable Angina Pectoris Undergoing Percutaneous Coronary Intervention. The American Journal of Cardiology. 105(3). 333–338. 34 indexed citations

15.

Kamphuisen, Pieter W., Izaak den Daas, Femke Van Bockstaele, et al.. (2009). Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Anti-Vwf Nanobody® ALX-0681 After Single and Multiple Subcutaneous Administrations to Healthy Volunteers.. Blood. 114(22). 1063–1063. 6 indexed citations

16.

Bartúnek, Jozef, et al.. (2008). Abstract 2009: ALX-0081 a Novel Anti-Thrombotic: Results of a Single-Dose Phase 1 Study in Healthy Volunteers and Further Development in Patients with Stable Angina Undergoing PCI. Circulation. 118(suppl_18). 7 indexed citations

17.

Nabid, Abdenour, John J. Kresl, Baldassarre Stea, et al.. (2004). Standard whole brain radiation (WBRT) with supplemental oxygen (O₂) with or without RSR13 (efaproxiral) in patients with brain metastases originating from NSCLC: Results of a subgroup analysis. Journal of Clinical Oncology. 22(14_suppl). 7115–7115. 1 indexed citations

18.

Suh, John H., Baldassarre Stea, Abdenour Nabid, et al.. (2004). Standard whole brain radiation therapy (WBRT) with supplemental oxygen (O₂), with or without RSR13 (efaproxiral)in patients with brain metastases: Results of the randomized REACH (RT-009) study. Journal of Clinical Oncology. 22(14_suppl). 1534–1534. 13 indexed citations

19.

Reck, Martin, et al.. (1997). 111 Chemotherapy of limited stage small cell lung cancer with carboplatin, paclitaxel and oral etoposide-A phase II-trial. Lung Cancer. 18. 31–31. 2 indexed citations

20.

Holz, Josefin-Beate, et al.. (1995). Limited sampling models for reliable estimation of etoposide area under the curve. European Journal of Cancer. 31(11). 1794–1798. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact